97 phenotypes from 13 alleles in 18 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Amhr2tm3(cre)Bhr/Amhr2+ Tsc2tm1.1Mjg/Tsc2tm1.1Mjg involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6	abnormal seminiferous tubule epithelium morphology	J:187754
	abnormal seminiferous tubule morphology	J:187754
	abnormal Sertoli cell morphology	J:187754
	abnormal spermatogenesis	J:187754
	abnormal testis morphology	J:187754
	decreased male germ cell number	J:187754
	decreased testis weight	J:187754
	increased Sertoli cell proliferation	J:187754
	normal neoplasm	J:187754
	small testis	J:187754
Tg(CMV-Tsc2*)1Arbi/0 involves: C57BL/6	abnormal cerebellum morphology	J:96943
	abnormal dermal layer morphology	J:96943
	abnormal motor learning	J:179850
	abnormal response to social novelty	J:179850
	abnormal social investigation	J:179850
	increased hamartoma incidence	J:96943
	increased skin hamartoma incidence	J:96943
	reduced long-term depression	J:182345
Tg(GFAP-cre)8Gtm/0 Tsc2tm1.1Mjg/Tsc2tm1.1Mjg involves: 129X1/SvJ * 129S1/Sv * C57BL/6 * CBA	abnormal hippocampus pyramidal cell morphology	J:167241
	astrocytosis	J:167241
	increased brain size	J:167241
	increased brain weight	J:167241
	premature death	J:167241
	seizures	J:167241
	slow postnatal weight gain	J:167241
Tg(Ins2-cre)23Herr/0 Tsc2tm1Kido/Tsc2tm1Kido involves: 129S4/SvJae * C57BL/6 * C57BL/6J * CBA/J	abnormal pancreatic islet morphology	J:135811
	decreased body weight	J:135811
	decreased circulating insulin level	J:135811
	decreased pancreatic beta cell number	J:135811
	hypoglycemia	J:135811
	improved glucose tolerance	J:135811
	increased circulating glucose level	J:135811
	increased circulating insulin level	J:135811
	increased insulin sensitivity	J:135811
	increased pancreatic beta cell mass	J:135811
	pancreatic islet hyperplasia	J:135811
Tg(Pcp2-cre)2Mpin/0 Tsc2tm1.1Mjg/Tsc2tm1.1Mjg involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	abnormal gait	J:174327
	abnormal Purkinje cell morphology	J:174327
	ataxia	J:174327
	impaired coordination	J:174327
	Purkinje cell degeneration	J:174327
Tg(Pcp2-cre)2Mpin/0 Tsc2tm1.1Mjg/Tsc2tm1.2Mjg involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	abnormal Purkinje cell morphology	J:174327
	postnatal lethality, incomplete penetrance	J:174327
	Purkinje cell degeneration	J:174327
	seizures	J:174327
Tsc2tm1.1Kcess/Tsc2tm1.1Kcess involves: 129S1/SvImJ * 129S4/SvJaeSor * 129S6/SvEvTac	no abnormal phenotype detected	J:195049
Tsc2tm1.1Kcess/Tsc2tm1.1Kcess Emx1tm1(cre)Krj/Emx1+ involves: 129S/Sv * C57BL/6J	decreased body weight	J:195049
	environmentally induced seizures	J:195049
	postnatal growth retardation	J:195049
	postnatal lethality, complete penetrance	J:195049
Tsc2tm1.1Kido/Tsc2+ involves: 129S4/SvJae * C57BL/6	increased kidney tumor incidence	J:135811
Tsc2tm1.1Mjg/Tsc2tm1.1Mjg involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	no abnormal phenotype detected	J:121748
Tsc2tm1.1Mjg/Tsc2tm1.1Mjg Pgrtm2(cre)Lyd/Pgr+ involves: 129S1/Sv * 129X1/SvJ	abnormal myometrium morphology	J:221228
	endometrium hyperplasia	J:221228
	enlarged uterus	J:221228
	increased endometrial gland number	J:221228
	increased lung tumor incidence	J:221228
	increased metastatic potential	J:221228
	increased uterus leiomyoma incidence	J:221228
	increased uterus weight	J:221228
	internal hemorrhage	J:221228
Tsc2tm1.2Mjg/Tsc2+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	increased adenoma incidence	J:121748
	kidney cyst	J:121748
Tsc2tm1.2Mjg/Tsc2tm1.2Mjg involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	embryonic growth retardation	J:121748
	embryonic lethality during organogenesis, incomplete penetrance	J:121748
Tsc2tm1Djk/Tsc2+ either: (involves: 129S4/SvJae * BALB/cJ) or (involves: 129S4/SvJae * Black Swiss) or (involves: 129S4/SvJae * C57BL/6J)	increased extremity angiosarcoma incidence	J:57631
	increased hepatic hemangioma incidence	J:57631
	increased lung adenoma incidence	J:57631
	increased renal carcinoma incidence	J:57631
	increased renal cystadenoma incidence	J:57631
	increased tumor incidence	J:57631
Tsc2tm1Djk/Tsc2+ involves: 129S4/SvJae * C57BL/6J	abnormal autophagy	J:217829
	abnormal dendritic spine morphology	J:217829
	abnormal response to novel object	J:217829
	abnormal response to social novelty	J:217829
	abnormal social investigation	J:217829
Tsc2tm1Djk/Tsc2+ involves: 129S4/SvJae * C57BL/6NCrl	abnormal contextual conditioning behavior	J:138621
	abnormal spatial learning	J:138621
	normal behavior/neurological phenotype	J:138621
	enhanced long-term potentiation	J:138621
	normal nervous system phenotype	J:138621
Tsc2tm1Djk/Tsc2tm1Djk either: (involves: 129S4/SvJae * BALB/cJ) or (involves: 129S4/SvJae * Black Swiss) or (involves: 129S4/SvJae * C57BL/6J)	embryonic lethality during organogenesis, complete penetrance	J:57631
	liver hypoplasia	J:57631
Tsc2tm1Jusa/Tsc2+ Not Specified	decreased myocardial infarct size	J:186597
	increased myocardial infarct size	J:186597
Tsc2tm1Kcess/Tsc2tm1Kcess involves: 129S1/SvImJ * 129S6/SvEvTac	preweaning lethality, complete penetrance	J:195049
Tsc2tm1Kido/Tsc2tm1Kido involves: 129S4/SvJae * C57BL/6	no abnormal phenotype detected	J:135811
Tsc2tm1Mjg/Tsc2+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6	kidney cyst	J:121748
Tsc2tm1Mjg/Tsc2tm1Mjg involves: 129S1/Sv * 129X1/SvJ * C57BL/6	decreased embryo size	J:121748
	embryonic lethality during organogenesis, incomplete penetrance	J:121748
	lethality throughout fetal growth and development, incomplete penetrance	J:121748
	open neural tube	J:121748
	pallor	J:121748
	prenatal lethality, complete penetrance	J:121748
Tsc2tm1Tno/Tsc2+ B6J.129S4-Tsc2tm1Tno	abnormal social investigation	J:221239
	decreased coping response	J:221239
	increased vertical activity	J:221239
Tsc2tm1Tno/Tsc2+ involves: 129S4/SvJae	abnormal dendrite morphology	J:222712
	abnormal dendritic spine morphology	J:222712
	normal nervous system phenotype	J:222712
Tsc2tm1Tno/Tsc2+ involves: 129S4/SvJae * C57BL/6J	increased hepatic hemangioma incidence	J:52464
	increased renal carcinoma incidence	J:52464
Tsc2tm1Tno/Tsc2tm1Tno involves: 129S4/SvJae * C57BL/6J	abnormal endocardium morphology	J:52464
	abnormal heart ventricle morphology	J:52464
	decreased embryo size	J:52464
	embryonic growth retardation	J:52464
	embryonic lethality during organogenesis, incomplete penetrance	J:52464
	heart hyperplasia	J:52464
	incomplete rostral neuropore closure	J:52464
	thick myocardium	J:52464
Tsc2tm2.1Djk/Tsc2tm2.1Djk involves: 129S4/SvJae * C57BL/6	no abnormal phenotype detected	J:149326
Tsc2tm2.2Djk/Tsc2+ involves: 129S4/SvJae * C57BL/6	increased renal cystadenoma incidence	J:149326
Tsc2tm2.2Djk/Tsc2tm2.2Djk involves: 129S4/SvJae * C57BL/6	abnormal embryonic hematopoiesis	J:149326
	abnormal vascular development	J:149326
	dilated vasculature	J:149326
	embryonic growth retardation	J:149326
	increased apoptosis	J:149326
	internal hemorrhage	J:149326
	lethality throughout fetal growth and development, complete penetrance	J:149326
	liver hypoplasia	J:149326
	normal nervous system phenotype	J:149326